A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Status Withdrawn

Clinical Trial Summary

This is a Phase II trial to study the safety and efficacy of IMMU-130. IMMU-130 is composed of a drug attached to an antibody. The drug is the active ingredient in irinotecan which is a common chemotherapy drug used for colorectal cancer. Antibodies are proteins normally made by the immune system. They bind to substances that don't belong in the body to prevent harm to the body. The antibody in this study was designed to bind to a marker located on colorectal cancer tumors. The antibody was originally made from mouse proteins, but was changed in the laboratory to be more like human antibodies. This study will investigate how IMMU-130 acts for the treatment of colorectal cancer. The study is mainly being done to see if IMMU-130 is safe and effective.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01915472
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Withdrawn
Phase	Phase 2
Start date	September 2013
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01228734` - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients	Phase 3
Completed	`NCT05178745` - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed	`NCT01591421` - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.	Phase 1/Phase 2
Withdrawn	`NCT05412706` - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy	Phase 2
Withdrawn	`NCT04430985` - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer	Phase 2
Withdrawn	`NCT03182894` - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05725200` - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer	Phase 2
Terminated	`NCT03176264` - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer	Phase 1
Completed	`NCT04866290` - HepaSphere™ Microspheres Prospective Registry
Not yet recruiting	`NCT06425133` - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers	Phase 2
Not yet recruiting	`NCT05531045` - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn	`NCT03982173` - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors	Phase 2
Completed	`NCT02906059` - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer	Phase 1
Active, not recruiting	`NCT02575378` - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer	Phase 4
Withdrawn	`NCT02535988` - Abscopal Effect for Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT02848807` - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life	N/A
Active, not recruiting	`NCT02077868` - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment	Phase 3
Completed	`NCT02414009` - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients	Phase 2
Active, not recruiting	`NCT01949194` - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers	Phase 2
Completed	`NCT01693848` - "Cancersensor" Metastasis Resection	N/A